What is TARGET? The Therapeutically
Applicable Research to Generate Effective Treatments (TARGET) Initiative seeks to
harness the power of modern genomics technologies to rapidly identify valid therapeutic
targets in childhood cancers so that new, more effective treatments can be developed
and ultimately bring new hope to children and their families who face the devastating
burden of these diseases.
Learn more
ARRA Supports TARGET Expansion; Five Childhood Tumors Now Being Analyzed
|
Five investigators have received Administrative Supplements using American Reinvestment and Recovery Act (ARRA) funding. This funding will add acute myelogenous leukemia, osteosarcoma and Wilms tumor to the TARGET portfolio and expand ongoing ALL and neuroblastoma research. Read more about the TARGET expansion. |
The TARGET Initiative pursues three primary areas of research:
The TARGET Initiative is currently focused on identifying therapeutic targets in five childhood cancers:
These cancers were the chosen for study because of their prevalence among children, the inadequacy of current treatment options and the availability of human tissue collections that met TARGET's strict scientific, technical, and ethical requirements. Learn more about the cancers selected for study by TARGET.
In the TARGET Initiative, the National Cancer Institute (NCI) actively collaborates with several world-class institutions to identify valid therapeutic targets in childhood cancers. Learn more
